Nuvo Pharmaceuticals (OTCMKTS:NRIFF) Issues Earnings Results

Nuvo Pharmaceuticals (OTCMKTS:NRIFF) released its quarterly earnings data on Wednesday. The company reported ($0.54) EPS for the quarter, Morningstar.com reports. Nuvo Pharmaceuticals had a negative return on equity of 21.93% and a negative net margin of 44.15%. The firm had revenue of $12.40 million during the quarter.

NRIFF stock traded up $0.08 during midday trading on Thursday, hitting $0.56. 1,000 shares of the company traded hands, compared to its average volume of 411. Nuvo Pharmaceuticals has a twelve month low of $0.45 and a twelve month high of $2.48. The company has a quick ratio of 1.91, a current ratio of 2.60 and a debt-to-equity ratio of 9.22. The firm’s 50 day simple moving average is $0.55.

About Nuvo Pharmaceuticals



Nuvo Pharmaceuticals Inc, a commercial healthcare company, produces and sells pharmaceutical products in the United States, Canada, and Europe. It offers Pennsaid, a topical pain product that is used to treat the signs and symptoms of osteoarthritis of the knee; Pennsaid 2%, a follow-on product to Pennsaid for the treatment of the pain of osteoarthritis of the knee; Heated Lidocaine/Tetracaine (HLT) Patch, a topical patch that provides local analgesia prior to painful needle procedures, such as dialysis, blood draws, and pediatric needles; and Resultz, an over-the-counter product intended to kill head lice and remove their eggs from hair.

See Also: How a Put Option Works

Earnings History for Nuvo Pharmaceuticals (OTCMKTS:NRIFF)

Receive News & Ratings for Nuvo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.